Add-on telitacicept improves clinical response in patients with active SLE
Telitacicept used in addition to standard therapy shows promising efficacy in Chinese patients with active systemic lupus erythematosus, suggests a phase 2b trial published in the Annals of the Rheumatic Diseases.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Cerliponase alfa treatment shows extended efficacy for CLN2 disease
Cerliponase alfa treatment slows the progression of neuronal ceroid lipofuscinosis type 2 disease for at least 5 years, shows an open-label extension study in The Lancet Neurology.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
VTE rates not significantly reduced by apixaban in paediatric ALL or lymphoma
Apixaban does not significantly reduce the rate of venous thromboembolism relative to standard care in paediatric patients with acute lymphoblastic leukaemia or lymphoma, show data from the phase 3 PREVAPIX-ALL trial.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Respiratory infection risk heightened in primary Sjögren’s syndrome and ILD
Patients with primary Sjögren’s syndrome and interstitial lung disease are at increased risk of respiratory infections, particularly bacterial infections, suggests a study published in Clinical Rheumatology.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Zonulin shows biomarker potential for celiac disease in at-risk children
Serum levels of the protein zonulin, high levels of which are associated with increased intestinal permeability, may be a useful biomarker for the development of celiac disease autoimmunity in children at genetic risk of the condition, suggest findings from the CD-GEMMA study.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Plasma p-tau217 may help select Alzheimer’s disease patients for anti-amyloid immunotherapy
Plasma phosphorylated (p)-tau217 may be an effective biomarker for identifying patients with Alzheimer’s disease who are most likely to benefit from anti-amyloid immunotherapies based on amyloid (A)β positivity and tau pathology, say investigators.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Remibrutinib shows promise for Sjögren’s syndrome treatment
The Bruton’s tyrosine kinase inhibitor remibrutinib reduces disease activity in patients with Sjögren’s syndrome, show results from the phase 2 LOUiSSE trial.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Young age reduces MS disability but does not fully protect against it
Progression of multiple sclerosis in the absence of relapses can occur at any age, although it is less common in children than adults with the condition, suggests research.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Cognitive decline continues during gantenerumab therapy for Alzheimer’s disease
Gantenerumab has failed to significantly slow cognitive impairment in people with early Alzheimer’s disease in the GRADUATE I and II trials of the anti-Aβ immunoglobulin G1 antibody.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Intestinal mucositis flags bloodstream infections in feverish children with leukaemia
Monitoring biomarkers of intestinal mucositis in children undergoing treatment for acute leukaemia who develop fever may identify those at risk for bloodstream infections (BSIs), Danish researchers have found.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
